chartexchange

MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026

PR Newswire | Nov 9, 2026 8:31 AM EST

CAMBRIDGE, Mass., Nov. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R)...

Read original article